Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

The pharmacokinetics, pharmacodynamics, and safety of zoledronic acid (Zometa), a new-generation bisphosphonate, were evaluated in 36 patients with cancer and bone metastases. Zoledronic acid (by specific radioimmunoassay) and markers of bone turnover were determined in plasma and urine after three consecutive infusions (qx28 days) of 4 mg15 min (n = 5), 4 mg/15 min (n = 7), 8 mg/15 min (n = 12), or 16 mg/15 min (n = 12). Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C-max to < 1% of C-max at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose. AUC(0-24 h), and C-max were dose proportional and showed little accumulation (AUC(0-24 h) ratio between the third and first dose was 1.28). Prolonging the infusion from 5 to 15 minutes lowered C-max by 34%, with no effect on AUC(0-24 h). Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae(0-24 h) of 38%+/-13%, 41%+/-14%, and 37%+/-17%, respectively, after 4, 8, and 16 mg. Only trace amounts of drug were detectable in post 24-hour urines. Renal clearance (Ae(0-24 h))/(AUC(0-24 h)) was on average 69+/-28, 81+/-40, and 54+/-34 ml/min after 4, 8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84+/-23, 82+/-25, and 80+/-40 ml/min for the dose groups at baseline. Adverse events and changes from baseline in vital signs and clinical laboratory variables showed no relationship in terms of type, frequency, or severity with zoledronic acid dose or pharmacokinetic parameters. Zoledronic acid produced significant declines from baseline in serum and/or creatinine-corrected urine C-telopeptide (by 74%), N-telopeptide (69%), pyridinium cross-links (19-33%), and calcium (62%), with an increasing trend(by 12%) in bone alkaline phosphatase. There was no relationship of the magnitude and duration of these changes with zoledronic acid dose, Ae(0-24 h), AUC(0-21 h) or C-max. The antiresorptive effects were evident within 1 day postdose and were maintained over 28 days across all dose levels, supporting monthly dosing with 4 mg zoledronic acid. (C) 2002 the American College of Clinical Pharmacology.